Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Matrixx unveils 2009 launches

This article was originally published in The Tan Sheet

Executive Summary

Xcid antacid product will debut early in fiscal year 2009, and will be positioned as a better tasting product than competing antacids, the Zicam marketer announces. "Consumers perceive liquid antacid products to be highly efficacious, but they taste very bad," Matrixx President and CEO Carl Johnson notes. Xcid will come in three 'soother' flavors: Milk Chocolate, Creamy Orange and Creamy Strawberry. Products will be sold in squeezable tubes and labels will feature the statement: "from the makers of Zicam." The formula contains maximum strength ingredients calcium carbonate and magnesium hydroxide, firm notes. Matrixx also will launch Zicare, the first OTC oral care product designed to dissolve tartar, in early 2008, according to Johnson. The cinnamon-flavored adhesive gel is applied to teeth after brushing. In developing the product over the past 18 months, the company has filed seven patents and conducted clinical trials. The product will be distributed in dental offices before rolling out to retailers in coming years, the company says...

You may also be interested in...

Slow Launch Of Xcid Antacid Spurs Matrixx To Marketing Changes

Matrixx Initiatives plans product-sampling and coupon-marketing activities as well as store displays in response to "small" sales of its latest product, Xcid antacid, the firm says

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.







Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts